Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 2Mesothelioma 2Lung Neoplasms 2Esophageal Neoplasms 2Thymus Neoplasms 1Sarcoma, Ewing 1Neoplasms, Germ Cell and Embryonal 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × Plicamycin × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡